Pharmaceutical FDM 3D printing (3DP) is revolutionizing the drug manufacturing industry globally by offering flexibility in design, dosing adjustments, rapid prototyping, and precise drug release control. The technology enables personalized pharmaceuticals, reduces development time, and transforms drug design and manufacturing processes. With its simplicity, cost-effectiveness, and strength, FDM technology is widely adopted in pharmaceuticals. Currently, the 3D-printed drug industry is at an early stage, mainly concentrated in Europe, the United States, and China, focusing on large-scale production and personalized drug delivery. While no regulatory guidelines exist yet, various countries are recognizing the potential of 3D printing in pharmaceuticals and are working towards establishing regulatory standards. Collaboration and partnerships on a global scale to advance FDM 3D printing in pharmaceuticals could lead to breakthroughs in personalized medicine, improved drug delivery, and enhanced patient care worldwide. The technology can establish scientific standards in the pharmaceutical field, driving innovation in drug development models. Efforts are ongoing to navigate unique registration paths for 3D-printed preparations, address intellectual property rights, and adapt drug regulations to this innovative technology. The promising future of the 3D-printed drug industry hinges on continuous efforts to promote intelligent and personalized drug preparation technologies through innovation and collaboration across diverse expertise and resources.